Abstract
Most patients with hypertension will require treatment with at least two antihypertensive agents to achieve blood pressure (BP) control. This double-blind study evaluated the efficacy and safety of aliskiren/amlodipine single-pill combination (SPC) therapy in patients with mild-to-moderate hypertension who are inadequately responsive to amlodipine monotherapy. Patients with mean sitting diastolic BP (msDBP) ≥ 90 and < 110 mmHg after 4 weeks’ treatment with amlodipine 10 mg were randomized to once-daily aliskiren/amlodipine 300/10 mg (n = 279) or 150/10 mg (n = 285) or amlodipine 10 mg monotherapy (n = 283) for 8 weeks. Aliskiren/amlodipine 300/10 and 150/10 mg SPCs provided significantly greater reductions in mean sitting systolic BP/msDBP (14.4/11.0 and 11.0/9.0 mmHg, respectively) than amlodipine 10 mg (8.2/7.2 mmHg) at week 8 endpoint. This represents additional mean reductions of 6.2/3.8 mmHg (300/10 mg) and 2.8/1.7 mmHg (150/10 mg) over amlodipine alone (all P < 0.01). Significantly more patients achieved BP control (< 140/90 mmHg) with aliskiren/amlodipine 300/10 mg (58.8%) than amlodipine 10 mg (38.4%; P < 0.0001). Aliskiren/amlodipine SPCs were generally well tolerated. In conclusion, aliskiren/amlodipine SPCs offers an effective option for management of patients who have an inadequate BP response to amlodipine alone.
Keywords: Aliskiren, amlodipine, single pill combination, hypertension, non- responder
Current Vascular Pharmacology
Title:Efficacy and Tolerability of Aliskiren/Amlodipine Single-Pill Combinations in Patients who did not Respond Fully to Amlodipine Monotherapy¥
Volume: 10 Issue: 6
Author(s): Dietrich Pfeiffer, Nicola Rennie, Cheraz C. Papst and Jack Zhang
Affiliation:
Keywords: Aliskiren, amlodipine, single pill combination, hypertension, non- responder
Abstract: Most patients with hypertension will require treatment with at least two antihypertensive agents to achieve blood pressure (BP) control. This double-blind study evaluated the efficacy and safety of aliskiren/amlodipine single-pill combination (SPC) therapy in patients with mild-to-moderate hypertension who are inadequately responsive to amlodipine monotherapy. Patients with mean sitting diastolic BP (msDBP) ≥ 90 and < 110 mmHg after 4 weeks’ treatment with amlodipine 10 mg were randomized to once-daily aliskiren/amlodipine 300/10 mg (n = 279) or 150/10 mg (n = 285) or amlodipine 10 mg monotherapy (n = 283) for 8 weeks. Aliskiren/amlodipine 300/10 and 150/10 mg SPCs provided significantly greater reductions in mean sitting systolic BP/msDBP (14.4/11.0 and 11.0/9.0 mmHg, respectively) than amlodipine 10 mg (8.2/7.2 mmHg) at week 8 endpoint. This represents additional mean reductions of 6.2/3.8 mmHg (300/10 mg) and 2.8/1.7 mmHg (150/10 mg) over amlodipine alone (all P < 0.01). Significantly more patients achieved BP control (< 140/90 mmHg) with aliskiren/amlodipine 300/10 mg (58.8%) than amlodipine 10 mg (38.4%; P < 0.0001). Aliskiren/amlodipine SPCs were generally well tolerated. In conclusion, aliskiren/amlodipine SPCs offers an effective option for management of patients who have an inadequate BP response to amlodipine alone.
Export Options
About this article
Cite this article as:
Pfeiffer Dietrich, Rennie Nicola, C. Papst Cheraz and Zhang Jack, Efficacy and Tolerability of Aliskiren/Amlodipine Single-Pill Combinations in Patients who did not Respond Fully to Amlodipine Monotherapy¥, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520945
DOI https://dx.doi.org/10.2174/157016112803520945 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Conventional Chemotherapy and Emerging Targeted Therapy for Advanced Adrenocortical Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Reactive Oxygen Species: Physiological Roles in the Regulation of Vascular Cells
Current Molecular Medicine Therapeutic Targets to Raise HDL in Patients at Risk or with Coronary Artery Disease
Current Vascular Pharmacology Natriuretic Peptides in Heart Failure and Post-Myocardial Infarction
Current Hypertension Reviews (Neuro)Transmitter Systems in Circulating Immune Cells: A Target of Immunopharmacological Interventions?
Current Medicinal Chemistry Modulation of Platelet Function and Signaling by Flavonoids
Mini-Reviews in Medicinal Chemistry Fluid and Electrolyte Disorders in the Newborn: Sodium and Potassium
Current Pediatric Reviews The Airway Neurogenic Inflammation: Clinical and Pharmacological Implications
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutic Use of Calcitriol
Current Vascular Pharmacology MicroRNA-mediated Regulation of Angiogenesis
Current Angiogenesis (Discontinued) Initiation of the Immune Response by Extracellular Hsp72: Chaperokine Activity of Hsp72
Current Immunology Reviews (Discontinued) Low Testosterone Levels and Metabolic Syndrome in Aging Male
Current Pharmaceutical Design 1+1 > 2: Integration of the Host-directed Traditional Chinese Medicine and the Virus-targeted Modern Medicine in Control of COVID-19
Clinical Cancer Drugs Ambulatory Blood Pressure Monitoring in Type 2 Diabetes Mellitus: A Cross-sectional Study
Current Hypertension Reviews Therapeutic Potential for Thyroid Hormone Receptor-β Selective Agonists for Treating Obesity, Hyperlipidemia and Diabetes
Current Vascular Pharmacology A Systematic Review of Drugs in Late-Stage Development for the Treatment of Multiple Sclerosis: A Focus on Oral Synthetic Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Emerging Nanocarriers-based Approaches to Diagnose and Red uce Vascular Inflammation in Atherosclerosis
Current Medicinal Chemistry Platelets and Vascular Risk: An Option for Treatment
Current Pharmaceutical Design The Frequency and Risk Factors of Diabetic Foot Ulcer Recurrence Among Jordanian Patients with Diabetes
Current Diabetes Reviews Role of NUCB2/nesfatin-1 in Glucose Control: Diverse Functions in Islets, Adipocytes and Brain
Current Pharmaceutical Design